Schering AG Agrees to Commercialise Praecis' Plenaxis™
By Business Review Editor
Pharma Deals Review: Vol 2004 Issue 48 (Table of Contents)
Published: 4 Jun-2004
DOI: 10.3833/pdr.v2004.i48.807 ISSN: 1756-7874
Section: Distribution & Marketing
Fulltext:
Abstract
Praecis formed an alliance with Schering to commercialize its prostate cancer drug Plenaxis(TM) in Europe, Middle East, South Africa, Australia and New Zealand...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS